Revisión

Pharmacological mechanisms of the treatment of dyskinesias in Parkinson’s disease

F. J. Jiménez-Jiménez, J.A. Molina, M. Ortí-Pareja DOI: https://doi.org/10.33588/rn.2809.98497 OPEN ACCESS
Volumen 28 | Number 09 | Nº of views of the article 4.022 | Nº of PDF downloads 479 | Article publication date 01/05/1999
Icono-PDF-OFF Download PDF Castellano Citation Search in PubMed
Share in: Facebook Twitter
Go to another issue
ABSTRACT Artículo en español English version
OBJECTIVE. The progression of Parkinson’s disease (PD) and levodopa therapy leads to development of motor and psychic complications that cause serious limitations to the management of the advanced disease. DEVELOPMENT. This article reviews the current literature regarding epidemiological, clinical, pathophysiological and therapeutics of levodopa-induced dyskinesias (LID).

CONCLUSIONS 1) The most important risk factors for LID are the cumulated doses of levodopa, young age at onset and severity of PD. 2) Pathophysiological data include the nigrostriatal system denervation, the prolonged exposure to levodopa and the integrity of striatal eferences; in addition there are some alterations of dopamine receptors and other neurotransmitter systems. 3) Some pharmacological measures, different for each type of LID, and surgery (pallidotomy, pallidal stimulation, subthalamic stimulation) can be useful for the therapy of LID
KeywordsDyskinesiasLevodopa therapyParkinson’s disease CategoriesNeurodegeneraciónPatología vascularTrastornos del movimiento
FULL TEXT (solo disponible en lengua castellana / Only available in Spanish)